Abstract ID: A32
Abstract Title: Kadian Is Effective, Safe, and Well Tolerated in Patients With Chronic, Non-Malignant, Moderate/Severe Pain: The KRONUS-MSP Trial
Poster Type: Poster
ABSTRACT BODY
Introduction:
This study evaluated the efficacy, safety, and effect on quality of life (QoL) of community-based treatment with Kadian (morphine sulfate sustained-release capsules) for chronic, non-malignant pain.
Materials and Methods:
This prospective, randomized, open-label, blinded endpoint study involved 1418 patients with diverse types of moderate to severe chronic, non-malignant pain. Baseline pain score on visual numeric scale (VNS) was ³4. All patients were switched from previous, unsuccessful pain treatment to Kadian, which was dosed Q24h in the AM or PM. Dose adjustments were permitted, but Q12h was not allowed until week 2. Final assessments at week 4 included pain relief (0–10 point VNS), sleep improvement (0–10 point VNS), adverse events, QoL (SF36v2 Health Survey), and treatment satisfaction (9-point Patient and Physician Global Assessment scale).
Results:
At week 4, all measures showed statistically significant improvement (p<0.001): pain relief (32%) and sleep (29%); SF36v2 composite scores for physical (12%) and mental (15.6%) functioning; and Patient (28%) and Physician (31%) Global Assessment. Kadian was well tolerated. Overall, 70% of patients (988/1418) completed the study; only 10% discontinued because of adverse events. Among the 40% of patients (563/1418) reporting adverse events, constipation (12%) and nausea (10%) were the most frequent. Results were comparable for AM and PM dosing groups.
Discussion:
In a community sample of patients with a broad range of moderate to severe chronic, non-malignant pain, Kadian was shown to be effective, safe, and well tolerated, with positive effects on QoL.
ATTACHED FILES
A32_Nicholson Fig. 1.doc
A32_Nicholson Fig. 2.doc
Reg Anesth Pain Med 2004; 29(2):A32